Morgan Stanley: Ultragenyx cuts R&D and pivots to commercialization; profitability in 2027 depends on new product launches
The company reaffirmed its full-year 2027 profitability target and plans to significantly reduce R&D expenses; however, Crysvita sales in the third quarter were below market expectations, and the rollout of two gene therapies will affect future growth.